We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab® Systems
News

Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab® Systems

Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab® Systems
News

Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab® Systems

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab® Systems"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Gyros AB announces that it has raised SEK 80 million (approximately €7.5m) in an equity fund raising led by SLS Invest, the Company’s leading shareholder.

The new funds will enable Gyros to drive the further commercialization of its Gyrolab technology. This technology platform is gaining traction with leading pharma and biotech companies as well as CROs and CMOs focused on the accelerated development of new biopharmaceuticals.

A growing list of more than 20 companies worldwide, including Merck, Medimmune, GSK, Amgen, Pfizer, Ablynx and ThromboGenics, currently benefit from Gyros’ unique Gyrolab systems, with an installed base of 40 systems.

SLS Invest is a Scandinavian life science investor and its decision to lead this funding round reflects confidence in the potential of Gyros’ automated micro-immunoassays for accelerating the development of therapeutic proteins. It also is in line with SLS Invest’s revised investment approach, which is centered on providing greater support to a smaller number of its portfolio companies.

SLS Invest’s confidence in Gyros’s future success is evidenced by the fact that, following the financing, it owns an 88% shareholding in Gyros.
Advertisement